Monitor for hematologic toxicity at baseline, every 2 weeks for the first 3 months, and for 2 weeks after discontinuation; test more frequently if signs of hematological changes occur. Discontinue ...
P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor (Brilinta, AstraZeneca) and ticlopidine) are indicated in all STEMI cases unless urgent surgery is required. Clopidogrel can also be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback